Bring Kyprolis to OBU Blue and Orange!!!! Former Onyx reps suck ass. They got Blincyto and couldn't sell. And they can't sell Kyprolis effectively! IF OBU HAD THIS, IT WOULD BE A ROCKSTAR! Unit demand only grew 8% sequentially from the third quarter, and sales only increased by $11 million. Don't get me wrong, this is good growth; but I think people were expecting great things from Kyprolis following its label expansion, not just good things. It's possible that an increase in competition could be to blame. In clinical studies, Johnson & Johnson's (NYSE:JNJ) and Genmab's Darzalex delivered a pretty stunning response rate of 29% in multiple myeloma patients who had received a median of five prior lines of therapy. It's possible that as Kyprolis expands into the second-line setting, that it could cede share in the third-line and higher setting to Johnson & Johnson's & Genmab's new drug. This will be something investors will want to closely monitor.
Because of the great Amgen OBU management. You Onyx people are still holding it back from 30-40% gains. We on orange and blue are waiting for you all to be fired. This is our glory!!! Not yours. It's only a matter of time before you have no critical mass left and you will be harassed us. They kept you separate at S1 but that won't last.
We in the OBU should try and get the kyprolis reps kicked out of our offices. This will speed up the process of us getting kyprolis in our bag.
Great idea! Why don't you throw the peas and carrots against the wall because you don't like peas and carrots? Wipe your own ass and get to work you baby!
